Valuation: Repare Therapeutics Inc.

Market Cap 112M 98.24M 90.81M 83.52M 158M 10.81B 160M 1.09B 426M 5.29B 421M 412M 18.22B P/E 2023
-3.28x
P/E 2024 -0.66x
Enterprise Value -38.78M -33.99M -31.42M -28.89M -54.52M -3.74B -55.39M -376M -147M -1.83B -146M -142M -6.3B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
6 months+2.71%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.48
Extreme 1.48
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
35.75
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 27/01/2026
Director TitleAgeSince
Director/Board Member - 27/01/2026
Date Insider Type Main position Quantity % Market Cap.
28/01/26 Issuer sale

Director

45,941 0.1066%
28/01/26 Issuer sale

Director

4,000 0.0093%
28/01/26 Issuer sale

Chairman

7,500 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+75.50%-75.84% 114M
-0.49%-4.01%+0.61%+2.28% 49.18B
-2.93%-0.13%+378.16%+584.97% 39.58B
-0.52%+2.77%+7.01%+61.95% 34.69B
-0.89%-0.97%+29.30%-9.20% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.37%-4.12% - - 16.21B
-2.06%+0.74%+72.92%+116.33% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.27%+0.28%+19.29%-32.68% 13.02B
Average -0.67%-0.06%+66.57%+77.40% 24.37B
Weighted average by Cap. -0.74%-0.59%+78.52%+121.09%

Financials

2023 2024
Net sales 51.13 44.82 41.43 38.1 71.89 4.93K 73.04 495.36 194.18 2.41K 192 187.82 8.31K 53.48 46.87 43.33 39.85 75.19 5.16K 76.39 518.07 203.08 2.52K 200.81 196.43 8.69K
Net income -93.8M -82.21M -75.99M -69.89M -132M -9.04B -134M -909M -356M -4.43B -352M -345M -15.25B -84.69M -74.23M -68.61M -63.11M -119M -8.17B -121M -820M -322M -4B -318M -311M -13.77B
Net Debt -220M -193M -178M -164M -310M -21.24B -315M -2.13B -836M -10.39B -827M -809M -35.8B -151M -132M -122M -112M -212M -14.55B -216M -1.46B -573M -7.12B -566M -554M -24.52B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock